Latest News

The 44th Congress of the ESCRS kicked off at ExCeL London with iNovation Day and the Opening Ceremony, setting the stage for a five-day programme.

Opus Genetics announced positive 3- and 6-month results OPGx-BEST1 in BEST1-related retinal diseases.

A JAMA Ophthalmology Clinical Trial of the Year enrolled 1421 eyes across 28 sites, with NEI-funded follow-up extending the findings to 5 years.

Handheld IC1000 pairs rebound tonometry with camera-guided alignment

Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Study authors discuss fishing-related eye injury patterns, pediatric risk, and prevention strategies drawn from other sports.

Women are more often affected than men, and the disease manifests differently between the sexes.

Ocugen's global phase 3 ArMaDa3 trial evaluates OCU410, a one-time gene therapy targeting multiple disease pathways in geographic atrophy secondary to dry age-related macular degeneration.

A same-platform, prospective comparison of 123 eyes suggests diffractive trifocal optics don't compromise standard automated perimetry outside the central 5°

Survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.

Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients with PRK.

Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.